Day: 7. March 2014

The compound (SYR-472) is a dipeptidyl peptidase-4 (DPP-4) inhibitor. Takeda launched alogliptin benzoate, another DPP-4 inhibitor, already in 2010. Nikkei Biotech news release, March 7, 2014

The antihypertension drug which achieved sales of about 2 bn US-$ in 2012 but is now off-patent may have been advertised by “inappropriate expressions”. An investigation by the Ministry of Health, Labour and Welfare is underway. China Bio news release, March 7, 2014